774
Views
21
CrossRef citations to date
0
Altmetric
Trends in Molecular Medicine

Phosphodiesterase genes and antidepressant treatment response: A review

, , , , &
Pages 177-185 | Received 23 Apr 2008, Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Jos Prickaerts, Pim R. A. Heckman & Arjan Blokland. (2017) Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert Opinion on Investigational Drugs 26:9, pages 1033-1048.
Read now
Julio Licinio & Ma-Li Wong. (2011) Pharmacogenomics of antidepressant treatment effects. Dialogues in Clinical Neuroscience 13:1, pages 63-71.
Read now
Gillian W Reierson, Claudio A Mastronardi, Julio Licinio & Ma-Li Wong. (2009) Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent. Clinical Pharmacology: Advances and Applications 1, pages 1-6.
Read now

Articles from other publishers (18)

Mohammad Amin Sadeghi, Ehsan Nassireslami, Mojtaba Yousefi Zoshk, Yasaman Hosseini, Kourosh Abbasian & Mohsen Chamanara. (2023) Phosphodiesterase inhibitors in psychiatric disorders. Psychopharmacology 240:6, pages 1201-1219.
Crossref
Mahmoud S. Abdallah, Ahmed N. Ramadan, Hend Omara‐Reda, Noha O. Mansour, Mohamed A. Elsokary, Hozaifa K. Elsawah, Shimaa Abdelsattar Zaki, Hend E. Abo Mansour & Esraa M. Mosalam. (2021) Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. CNS Neuroscience & Therapeutics 27:12, pages 1540-1548.
Crossref
Sébastien Delhaye & Barbara Bardoni. (2021) Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders. Molecular Psychiatry 26:9, pages 4570-4582.
Crossref
Seyed Mohammad Nabavi, Sylwia Talarek, Joanna Listos, Seyed Fazel Nabavi, Kasi Pandima Devi, Marcos Roberto de Oliveira, Devesh Tewari, Sandro Argüelles, Saeed Mehrzadi, Azam Hosseinzadeh, Grazia D'onofrio, Ilkay Erdogan Orhan, Antoni Sureda, Suowen Xu, Saeedeh Momtaz & Mohammad Hosein Farzaei. (2019) Phosphodiesterase inhibitors say NO to Alzheimer's disease. Food and Chemical Toxicology 134, pages 110822.
Crossref
Li Liu, Jing Zheng, Xian-Feng Huang, Xia Zhu, Shu-Ming Ding, Heng-Ming Ke, James M. O'Donnell, Han-Ting Zhang, Guo-Qiang Song & Ying Xu. (2018) The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor. CNS Neuroscience & Therapeutics 24:7, pages 652-660.
Crossref
P.R.A. Heckman, A. Blokland, E.P.P. Bollen & J. Prickaerts. (2018) Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. Neuroscience & Biobehavioral Reviews 87, pages 233-254.
Crossref
Brian Dyck, Bryan Branstetter, Tawfik Gharbaoui, Andrew R. Hudson, J. Guy Breitenbucher, Laurent Gomez, Iriny Botrous, Tami Marrone, Richard Barido, Charles K. Allerston, E. Peder Cedervall, Rui Xu, Vandana Sridhar, Ryan Barker, Kathleen Aertgeerts, Kara Schmelzer, David Neul, Dong Lee, Mark Eben Massari, Carsten B. Andersen, Kristen Sebring, Xianbo Zhou, Robert Petroski, James Limberis, Martin Augustin, Lawrence E. Chun, Thomas E. Edwards, Marco Peters & Ali Tabatabaei. (2017) Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties. Journal of Medicinal Chemistry 60:8, pages 3472-3483.
Crossref
Pim R. A. Heckman, Marlies A. van Duinen, Eva P. P. Bollen, Akinori Nishi, Lawrence P. Wennogle, Arjan Blokland & Jos Prickaerts. (2016) Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications. International Journal of Neuropsychopharmacology 19:10, pages pyw030.
Crossref
Zhuoyou Chen, Xifei Yang, Ying Xu & Han-Ting Zhang. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy 805 823 .
J J Luykx, S C Bakker, E Lentjes, M Neeleman, E Strengman, L Mentink, J DeYoung, S de Jong, J H Sul, E Eskin, K van Eijk, J van Setten, J E Buizer-Voskamp, R M Cantor, A Lu, M van Amerongen, E P A van Dongen, P Keijzers, T Kappen, P Borgdorff, P Bruins, E M Derks, R S Kahn & R A Ophoff. (2013) Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid. Molecular Psychiatry 19:2, pages 228-234.
Crossref
Jos Prickaerts. 2010. Encyclopedia of Psychopharmacology. Encyclopedia of Psychopharmacology 1 12 .
Laurent Gomez & J. Guy Breitenbucher. (2013) PDE2 inhibition: Potential for the treatment of cognitive disorders. Bioorganic & Medicinal Chemistry Letters 23:24, pages 6522-6527.
Crossref
Ana Blazquez, Sergi Mas, Ma Teresa Plana, Amàlia Lafuente & Luisa Lázaro. (2012) Fluoxetine pharmacogenetics in child and adult populations. European Child & Adolescent Psychiatry 21:11, pages 599-610.
Crossref
B M Andrus, K Blizinsky, P T Vedell, K Dennis, P K Shukla, D J Schaffer, J Radulovic, G A Churchill & E E Redei. (2010) Gene expression patterns in the hippocampus and amygdala of endogenous depression and chronic stress models. Molecular Psychiatry 17:1, pages 49-61.
Crossref
Dhaval Nanavati, Daniel R. Austin, Lisa A. Catapano, David A. Luckenbaugh, Ayse Dosemeci, Husseini K. Manji, Guang Chen & Sanford P. Markey. (2011) The effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome. Journal of Neurochemistry 119:3, pages 617-629.
Crossref
Cecilio Lopez-Munoz & Francisco AlamoYing Xu, Han-Ting Zhang & James O’Donnell. 2011. Neurobiology of Depression. Neurobiology of Depression 419 444 .
Mehdi Ghasemi & Ahmad Reza Dehpour. (2011) The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends in Pharmacological Sciences 32:7, pages 420-434.
Crossref
Ying Xu, Han-Ting Zhang & James M. O’Donnell. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets 447 485 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.